Rohto Pharmaceutical - Company History
- Founding
- In February 1899 Yamada Yasutami founded Shintendo Yamada Yasutami Yakubo in Osaka and put the stomach medicine Ikatsu on sale. Eye drops followed, and from then on the range was narrowed to those two lines. Yamada Teruo, the second-generation head, drilled into the company a policy of few products in high volume — good products delivered cheaply to the mass market. That no outside capital was taken in, and that the Yamada family held the large shareholdings, is what allowed the choice not to add brands but to mass advertising behind a limited set of items. Rohto took a 40% domestic share in stomach medicines and in eye drops alike and built its standing as an OTC drug maker. In August 1975 it acquired the Mentholatum trademark licence, left in limbo by the collapse of Omi Brotherhood, adding ointments as a third line.
- The Decision
- It turned a borrowed brand into one it owned outright. A trademark licence left the company's hands tied whenever the contract came up for revision or the royalty terms were rethought, so in July 1988 it bought the American Mentholatum Company and took hold of the trademark together with the manufacturing and sales rights as a single package. That sovereignty became bargaining material when joint ventures were set up across Asia — China in 1991, Indonesia in 1996, Vietnam in 1997. At home it began full-scale investment in skincare in 2001 and launched Hada Labo, carrying its dermatological knowledge into a hyaluronic-acid lotion. Few pharmaceutical companies have made cosmetics pay, and Rohto raised a fourth earnings stream from nothing after stomach medicines, eye drops and ointments.
- Today
- Half of sales now stand outside Japan. Of revenue of $2.2B (¥344bn) in the year to March 2026, Japan accounted for $1.1B (¥169bn), Asia for $792.2M (¥125bn), Europe for $151.1M (¥24bn) and the Americas for $136.6M (¥22bn). Operating profit of $259.9M (¥41bn) breaks down as $139.7M (¥22bn) in Japan against $94.8M (¥15bn) in Asia. The trademark sovereignty taken in 1988 has, nearly forty years on, turned into earnings in the form of a network of Asian subsidiaries. In April 2024 the company acquired, jointly with Mitsui & Co., the Singapore traditional-medicine group Eu Yan Sang, supplementing a range weighted towards skincare with oral medicines and foods. Since 2013 it has been directing the money earned in OTC drugs and cosmetics into regenerative medicine, and development of ADR-001, an allogeneic adipose-derived stem-cell preparation, continues.
- Competition
- Among the family-run makers of OTC medicines, Rohto alone chose both a listing and a president from outside. Taisho Pharmaceutical Holdings delisted in 2023 through a management buyout by its founding family, taking that family off the market. Kobayashi Pharmaceutical, after the red-yeast-rice affair of 2024, moved in 2026 to a company with an audit and supervisory committee under pressure from an activist shareholder. Rohto has stayed listed with the Yamada family still among its large shareholders, and after the sudden death of President Yoshino Toshiaki in 2018 it brought in Sugimoto Masashi from Takeda Pharmaceutical as its first president from outside the company. Ownership and execution are being pulled apart. The domestic OTC market is mature, and the competitive question is not the merits of a formulation but where the money earned is moved to — traditional medicine, or regenerative medicine.
Timeline
1899–1983Building an OTC drug maker, and reshaping the portfolio
- 1899Yamada Yasutami founds Shintendo Yamada Yasutami Yakubo in Osaka and launches the stomach medicine Ikatsu
- 1909Launch of Rohto eye drops, named for Dr Rothmund's prescription
- 1931The Rohto dropper bottle is devised and demand for eye drops surges
- 1949Reorganised as a joint-stock company: Rohto Pharmaceutical Co., Ltd.
- 1954Launch of the stomach medicine Shiron
- 1959New head-office plant completed
- 1961Listed on the second section of the Osaka Securities Exchange
- 1963Launch of the general stomach remedy Pansiron
- 1964Launch of V Rohto; designated to the first sections in Tokyo and Osaka; Rohto-kai dealer network formed
- 1975Acquires the Mentholatum trademark licence and enters the ointment market; buys Nihon Josephine and two other firms; enters cosmetics
- 1983Loses the top domestic share in stomach medicines
1984–1998Buying Mentholatum, and building the Asian business in earnest
- 1988Acquires the Mentholatum Company of the United States as a wholly owned subsidiary
- 1991Establishes a joint venture in China with the Mentholatum Company
- 1996Official sponsor of the Chinese diving team at the Atlanta Olympics, which takes six golds
- 1996Rohto Indonesia established in September
- 1997Rohto-Mentholatum Vietnam established in August
- 1998Rohto USA established in March
- 1998New plant built at Orchard Park, New York
1999–2026Investing in skincare, and turning into an integrated healthcare company
- 1999Yamada Yasukuni becomes chairman and Yamada Kunio president
- 2001Full-scale investment in skincare begins; Hada Labo is developed
- 2003Strategic business alliance concluded with Morishita Jintan in September
- 2013Regenerative Medicine Research Planning Department established
- 2013Enters regenerative medicine using allogeneic adipose-derived mesenchymal stem cells
- 2014Acquires shares in Yaeyama Farm in March, lifting its stake to 49.9%
- 2016Outside Challenge Work scheme begins in February, permitting employee side-jobs
- 2018President Yoshino Toshiaki dies suddenly; Yamada Kunio returns as chairman and president
- 2019Sugimoto Masashi becomes president in June — the first from outside the company
- 2020Japan Ophthalmic Laboratory (日本点眼薬研究所) made a subsidiary in March
- 2021Amato Pharmaceutical Products made a subsidiary in August
- 2022Sales-promotion spending held down; margins improve for a third consecutive year
- 2024Eu Yan Sang International made a subsidiary in June
Founding Story
1899–1983Building an OTC drug maker, and reshaping the portfolio
Rohto Pharmaceutical was founded in Osaka in February 1899 as the maker of a single stomach medicine, and for the next eighty years it grew by narrowing rather than widening: two mainstay categories, stomach medicines and eye drops, each carried to a 40% domestic share on advertising massed behind a handful of brands, with sales rising from $7.2M (¥3bn) in the year to July 1959 to $63.2M (¥15bn) by 1983. The very concentration that produced those shares left the company without a range to answer with when the stomach-medicine market broke apart into symptom-specific remedies, and in 1983 the lead it had held for decades went to a rival.
A few products in enormous volume — the 40% share and its high-turnover economics
In February 1899 Yamada Yasutami (山田安民) founded Shintendo Yamada Yasutami Yakubo (信天堂山田安民薬房) at Shimizucho in Minami-ku, Osaka[1], and began manufacturing and selling the stomach medicine Ikatsu (胃活). The business also went abroad, setting up the subsidiary Yamada Pharmaceutical in Shanghai in 1938[2] and Manchuria Yamada Pharmaceutical in Hoten (奉天, present-day Shenyang) in 1941[3] to widen its sales channels across the Chinese mainland; the end of the Pacific War wiped out those overseas assets at a stroke[4], and the business base was re-concentrated at home. In September 1949 the proprietorship was reorganised into a joint-stock company, and Rohto Pharmaceutical Co., Ltd. was incorporated with capital of $27,778 (¥10m)[5]. Yamada Teruo (山田輝郎) of the founding family took the presidency, deliberately avoiding any intake of outside capital so that management control stayed with the Yamada family. Even after the company listed on the second section of the Osaka Securities Exchange in 1961, most of its large shareholders were members of the Yamada family, and family control was institutionally set. That the capital structure and management control were fused at the fifty-year mark became the foundation for the independence of the company's long-horizon business decisions.
In 1909 the company launched Rohto eye drops (ロート目薬). The product name derived from the prescription of Dr Rothmund (ロートムンド博士), a professor at the University of Munich in Germany[6], and the drops were a departure; when the company devised the Rohto dropper bottle in 1931[7], demand for eye drops surged. After the war it fielded new products in quick succession — Rohto Penimai eye drops (ロートペニマイ目薬) in 1952, the stomach medicine Shiron (シロン) in 1954 and Shin Rohto eye drops (新ロート目薬) in 1958[8] — followed by the general stomach remedy Pansiron (パンシロン) in 1963 and the premium ophthalmic preparation V Rohto (Vロート) in 1964[9]. In the same year it launched Rohto-kai (ロート会), a sales network made up of leading retailers nationwide[10], and pushed these mainstay lines into wide distribution. Yamada Teruo narrowed the range of items and drilled into the company a policy of few products in high volume — good products delivered cheaply to the mass market. Rohto secured a 40% domestic share in stomach medicines and in eye drops alike, and built its standing as an OTC drug maker on a selling method that massed advertising spend behind a limited set of brands. Against rivals running many items in parallel, Rohto's contrarian concentration on a few mainstays compressed manufacturing cost and selling expense and stacked up high-turnover earnings.
Losing the stomach-medicine lead in 1983 — the flip side of concentration
In the late 1970s Japan's stomach-medicine market entered maturity, and makers found themselves fighting over existing demand. Pansiron held the line as the flagship general remedy, and as a result lost share among its core users to rivals with tightly targeted products. In a market structure into which symptom-specific remedies — for heartburn, for a heavy stomach, for drinking too much — were being launched with advertising behind them, Rohto, whose flagship was the general type, was slow to respond. In 1983 the company surrendered the top domestic share in stomach medicines to a competitor, and that arrangement stayed fixed thereafter. The strength of concentrating on a few products rebounded as a weakness: at the moment the market fragmented, it lacked agility of range. The high-turnover model that had worked in the expansion phase told in reverse as a constraint in maturity.
Rohto had in fact been moving since the 1970s to avoid excessive dependence on stomach medicines. In August 1975 it acquired from the American Mentholatum Company the right to use the Mentholatum trademark, left in limbo by the collapse of Omi Brotherhood (近江兄弟社), and entered the ointment market in earnest. The terms were a ten-year contract at a royalty of 7.5% of sales — a method of drawing on a known brand rather than developing one in-house. The advantage was large: it could skip the advertising investment needed to build recognition from scratch while inheriting an established user base. That losing the top share in stomach medicines did only limited damage to overall results was the work of this third earnings stream; moving early on the reshaping of the portfolio acted as a shock absorber.
1984–1998Buying Mentholatum, and building the Asian business in earnest
The fifteen years from 1984 turned a borrowed brand into an owned one: Rohto bought the Mentholatum Company of the United States outright in 1988, then used the trademark it now controlled as the axis of an Asian expansion running from a Chinese joint venture to subsidiaries in Indonesia, Vietnam and the United States, with sales climbing from $66.1M (¥16bn) to $304.8M (¥40bn). Overseas ceased to be an export destination and became the growth the mature home market could no longer supply.
The Mentholatum acquisition — from licence to ownership
In July 1988 Rohto acquired the Mentholatum Company of the United States and made it a wholly owned subsidiary. The purchase came in response to an approach from the other side. Remaining dependent on a licence carried the risk that contract revisions or a rethink of royalty terms would constrain the company's freedom of action; by acquiring the source company itself, Rohto took hold of manufacturing, sales and trademark rights as a single package and switched to a structure released from renewal risk. It was Rohto's first full-scale acquisition of an overseas company, and the starting point of its international expansion thereafter. Thirteen years after taking the licence in 1975, the company had raised its third earnings stream in ointments from a contractual footing to an ownership footing.
After the acquisition the company shifted its main effort to a global expansion built around the Mentholatum brand. Omi Brotherhood returned to the market with the Menturm (メンターム) brand, so that a three-way contest settled in at home; overseas, however, Rohto held brand sovereignty and stood at an advantage in both pricing power and the right to decide what to launch. The company did not leave Mentholatum as a domestic ointment brand but placed it at the axis of an international business centred on Asia. Once the maturity of the home market had been laid bare by the loss of the stomach-medicine lead, making overseas the next earnings stream was an unavoidable course. The trademark sovereignty won in the acquisition then served as a bargaining trump card in the joint ventures set up across Asian countries.
The China joint venture, and six Atlanta gold medals that carried the brand across Asia
In 1991 Rohto, together with the American Mentholatum Company, established a joint venture in China and entered the Asian market in earnest. At the 1996 Atlanta Olympics it became the official sponsor of the Chinese diving team, and brand recognition spread in step with the team's six gold medals. The need for overseas growth to answer the maturity of the home market had been shared inside the company as a management problem ever since the loss of the stomach-medicine lead, and the decision to make China the first foothold followed from it. Consumer exposure through sports sponsorship was a means of standing up local brand recognition quickly in an emerging market with little advertising spend. As the axis complementing a mature Japanese market, the company chose a route that accumulated local recognition in Asia without paying for advertising to get it.
It established Rohto Indonesia in Indonesia in 1996 and Rohto-Mentholatum Vietnam in Vietnam in 1997[11], putting manufacturing and sales bases into South-East Asia. In 1998 it set up Rohto USA in the United States, siting the base at Orchard Park, New York, where the Mentholatum Company's head office and plant stood. The Asian business built around China grew into a third operating base after Japan and the United States, and the ratio of overseas sales rose. This was the course by which the brand sovereignty won in the 1988 Mentholatum acquisition turned, ten years on, into earnings in the form of a multi-site Asian presence. An overseas expansion that had begun with a licence had become a structure combining ownership of the brand with a network of local subsidiaries.
Notes
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968↩
- Rohto Pharmaceutical, annual securities report, corporate history section↩
References & sources
- Rohto Pharmaceutical Co., Ltd. (annual securities reports), including the corporate-history section, the source for consolidated and parent-only figures from the 1960s onward.
- Corporate Histories: A Century of Meiji, Keizai Shunju-sha (1968), the Rohto Pharmaceutical entry.
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; revenue charts are shown in yen. Exchange rates & sources — the full ¥/US$ table →
Data API
Rohto Pharmaceutical’s history, presidents and financials
are published as static JSON — no key, plain GET. One API per
public page, and one per section where a page carries several tables.
Full specification →
/api/4527/company.json ·/api/4527/history.json ·/api/4527/ceo.json ·/api/4527/financials.json ·/api/4527/financials/segment.json ·/api/4527/financials/pl.json ·/api/4527/financials/cf.json ·/api/4527/financials/bs.json ·/api/4527/financials/employee.json ·/api/4527/financials/stock.json ·/api/4527/financials.csv ·/api/4527/financials_history.csv
/api/companies.json ·/api/decisions.json ·/api/api-manifest.json